Structural comparison of typical and atypical E2 pestivirus glycoproteins

Molecular detection and genotyping of bovine viral diarrhea virus in four provinces of China

Bovine viral diarrhea virus (BVDV) is one of the major pathogens hindering the development of the global beef industry. To investigate the epidemic profile and genetic diversity of this virus, a total of 77 fecal samples were collected from cattle with diarrhea in Henan, Sichuan, Shandong, and Hebei provinces of China during 2023-2024 and screened for the presence of BVDV using reverse transcription polymerase chain reaction (RT-PCR). The results showed that 35 of the 77 bovine samples (45%) were positive for BVDV, with the highest positive rate of 26% (20/77) in Henan province. The 5'-UTR sequences of the viruses from 21 positive samples and the whole-genome sequence from one sample (BVDV-385) were determined and analyzed. The 5'-UTR sequences from this study were 74.7-96.4% identical to those of 23 reference sequences. Phylogenetic analysis based on the 5'-UTR sequences indicated that 20 of the strains belonged to the subtype BVDV-1m, while only one, BVDV-385 from Henan province, belonged to genotype BVDV-3. Analysis of the genome sequence of strain BVDV-385 showed that its E2 protein has a unique amino acid (aa) deletion and ten unique aa substitutions, and its NS5B protein has seven unique aa substitutions. The variations were predicted to affect four potential linear B cell epitopes in the E2 protein and to introduce a potential non-canonical N-glycosylation site (574 NPS) in the NS5B protein. The results of this study contribute to our understanding of the genetic diversity of BVDV in China.

Modulation of ADAM17 Levels by Pestiviruses Is Species-Specific

Upon host cell infection, viruses modulate their host cells to better suit their needs, including the downregulation of virus entry receptors. ADAM17, a cell surface sheddase, is an essential factor for infection of bovine cells with several pestiviruses. To assess the effect of pestivirus infection on ADAM17, the amounts of cellular ADAM17 and its presence at the cell surface were determined. Mature ADAM17 levels were reduced upon infection with a cytopathic pestivirus bovis (bovine viral diarrhea virus, cpBVDV), pestivirus suis (classical swine fever virus, CSFV) or pestivirus giraffae (strain giraffe), but not negatively affected by pestivirus L (Linda virus, LindaV). A comparable reduction of ADAM17 surface levels, which represents the bioactive form, could be observed in the presence of E2 of BVDV and CSFV, but not LindaV or atypical porcine pestivirus (pestivirus scrofae) E2. Superinfection exclusion in BVDV infection is caused by at least two proteins, glycoprotein E2 and protease/helicase NS3. To evaluate whether the lowered ADAM17 levels could be involved in superinfection exclusion, persistently CSFV- or LindaV-infected cells were challenged with different pestiviruses. Persistently LindaV-infected cells were significantly more susceptible to cpBVDV infection than persistently CSFV-infected cells, whilst the other pestiviruses tested were not or only hardly able to infect the persistently infected cells. These results provide evidence of a pestivirus species-specific effect on ADAM17 levels and hints at the possibility of its involvement in superinfection exclusion.

Mapping glycoprotein structure reveals Flaviviridae evolutionary history

Viral glycoproteins drive membrane fusion in enveloped viruses and determine host range, tissue tropism and pathogenesis1. Despite their importance, there is a fragmentary understanding of glycoproteins within the Flaviviridae2, a large virus family that include pathogens such as hepatitis C, dengue and Zika viruses, and numerous other human, animal and emergent viruses. For many flaviviruses the glycoproteins have not yet been identified, for others, such as the hepaciviruses, the molecular mechanisms of membrane fusion remain uncharacterized3. Here we combine phylogenetic analyses with protein structure prediction to survey glycoproteins across the entire Flaviviridae. We find class II fusion systems, homologous to the Orthoflavivirus E glycoprotein in most species, including highly divergent jingmenviruses and large genome flaviviruses. However, the E1E2 glycoproteins of the hepaciviruses, pegiviruses and pestiviruses are structurally distinct, may represent a novel class of fusion mechanism, and are strictly associated with infection of vertebrate hosts. By mapping glycoprotein distribution onto the underlying phylogeny, we reveal a complex evolutionary history marked by the capture of bacterial genes and potentially inter-genus recombination. These insights, made possible through protein structure prediction, refine our understanding of viral fusion mechanisms and reveal the events that have shaped the diverse virology and ecology of the Flaviviridae.

Recombinant Subunit Vaccine Candidate against the Bovine Viral Diarrhea Virus

Multivalent live-attenuated or inactivated vaccines are often used to control the bovine viral diarrhea disease (BVD). Still, they retain inherent disadvantages and do not provide the expected protection. This study developed a new vaccine prototype, including the external segment of the E2 viral protein from five different subgenotypes selected after a massive screening. The E2 proteins of every subgenotype (1aE2, 1bE2, 1cE2, 1dE2, and 1eE2) were produced in mammalian cells and purified by IMAC. An equimolar mixture of E2 proteins formulated in an oil-in-water adjuvant made up the vaccine candidate, inducing a high humoral response at 50, 100, and 150 µg doses in sheep. A similar immune response was observed in bovines at 50 µg. The cellular response showed a significant increase in the transcript levels of relevant Th1 cytokines, while those corresponding to the Th2 cytokine IL-4 and the negative control were similar. High levels of neutralizing antibodies against the subgenotype BVDV1a demonstrated the effectiveness of our vaccine candidate, similar to that observed in the sera of animals vaccinated with the commercial vaccine. These results suggest that our vaccine prototype could become an effective recombinant vaccine against the BVD.